The haemodynamic effects of oXiris haemofilter in septic shock patients requiring renal support: A single-centre experience

Abstract

Excessive pro-inflammatory and anti-inflammatory cytokines are mediators for haemodynamic alterations, metabolic acidosis, and multi-organ failure in sepsis. Recently, oXiris^® haemofilter (Baxter, IL, USA) has been introduced as a novel haemofilter to mitigate inflammatory response during sepsis-associated acute kidney injury requiring renal replacement therapy. In the present case series, the researchers retrospectively reviewed critically ill patients with septic shock with the use of at least one oXiris haemofilter during continuous renal replacement therapy between June 2015 and December 2017. The timing for oXiris initiation was at the nephrologists’ discretion. The impact of oXiris haemofilter was evaluated on mean arterial pressure, vasopressor dosage, Sequential Organ Failure Assessment score, lactate and base excess during 72 h after treatment. Thirty-five patients were enrolled in the study. An improvement of haemodynamic status was found, shown by increased mean arterial pressure by 6.1% (p = 0.35), decreased norepinephrine dose by 45.9% (p = 0.02), inotropic score by 26.4% (p = 0.02) and vasopressor dependency index by 40.5% (p = 0.01). Cardiovascular Sequential Organ Failure Assessment scores significantly decreased over 72 h (p = 0.02). Blood lactate levels and base excess also showed statistically significant improvements. The median filter lifetime was 23 (interquartile range = 14–36) hours. The intensive care unit mortality was 82.9%. Treatment with oXiris was safe and well-tolerated with no device-related adverse events. In conclusion, continuous renal replacement therapy with oXiris haemofilter is safe and may improve haemodynamic parameters in septic patients with severe renal dysfunction. Nonetheless, these findings were drawn from a retrospective analysis without a control group, and therefore cannot be generalised. Randomised controlled trials are warranted to confirm these findings.

Keywords

oXiris haemofilter continuous renal replacement therapy septic shock

Get full access to this article

View all access options for this article.

References

Singer

Deutschman

Seymour

, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA 2016; 315(8): 801–810.

Angus

van der Poll

Severe sepsis and septic shock. N Engl J Med 2013; 369(21): 2063.

Engel

Brunkhorst

Bone

, et al. Epidemiology of sepsis in Germany: results from a national prospective multicenter study. Intensive Care Med 2007; 33(4): 606–618.

Mouncey

Osborn

Power

, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med 2015; 372(14): 1301–1311.

Peake

Delaney

Bailey

, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med 2014; 371(16): 1496–1506.

Yealy

Kellum

Huang

, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014; 370(18): 1683–1693.

Cecconi

Evans

Levy

, et al. Sepsis and septic shock. Lancet 2018; 392(10141): 75–87.

Ikeda

Suda

, et al. Usefulness of the endotoxin activity assay as a biomarker to assess the severity of endotoxemia in critically ill patients. Innate Immun 2014; 20(8): 881–887.

Cohen

The immunopathogenesis of sepsis. Nature 2002; 420(6917): 885–891.

10.

Srisawat

Tungsanga

Lumlertgul

, et al. The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients. Crit Care 2018; 22(1): 279.

11.

Cruz

Antonelli

Fumagalli

, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009; 301(23): 2445–2452.

12.

Payen

Guilhot

Launey

, et al. Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial. Intensive Care Med 2015; 41(6): 975–984.

13.

Dellinger

Bagshaw

Antonelli

, et al. Effect of targeted polymyxin B hemoperfusion on 28-day mortality in patients with septic shock and elevated endotoxin level: the EUPHRATES randomized clinical trial. JAMA 2018; 320(14): 1455–1463.

14.

Klein

Foster

Walker

, et al. Polymyxin B hemoperfusion in endotoxemic septic shock patients without extreme endotoxemia: a post hoc analysis of the EUPHRATES trial. Intensive Care Med 2018; 44(12): 2205–2212.

15.

Monard

Rimmele

Ronco

Extracorporeal blood purification therapies for sepsis. Blood Purif 2019; 47(Suppl. 3): 2–15.

16.

Rhodes

Evans

Alhazzani

, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Intensive Care Med 2017; 43(3): 304–377.

17.

Gambro Industries. oXiris preclinical data and clinical evaluation 2007. https://www.baxter.com/healthcare-professionals/critical-care/oxiris-critical-care

18.

Hattori

Oda

Cytokine-adsorbing hemofilter: old but new modality for septic acute kidney injury. Ren Replace Ther 2016; 2(1): 41.

19.

Rimmele

Assadi

Cattenoz

, et al. High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009; 24(2): 421–427.

20.

Malard

Lambert

Kellum

JA.

In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp 2018; 6(1): 12.

21.

Turani

Candidi

Barchetta

, et al. Continuous renal replacement therapy with the adsorbent membrane oXiris in septic patients: a clinical experience. Critical Care 2013; 17(Suppl. 2): P63.

22.

Shum

Chan

KCKC

Kwan

, et al. Application of endotoxin and cytokine adsorption haemofilter in septic acute kidney injury due to Gram-negative bacterial infection. Hong Kong Med J 2013; 19: 491–497.

23.

Adamik

Smiechowicz

Zielinski

, et al. Use of extracorporeal endotoxin elimination therapy for septic shock. Critical Care 2013; 17(2): P66.

24.

Tan

Kaushik

Tan

, et al. Augmented adsorptive blood purification during continuous veno-venous haemodiafiltration in a severe septic, acute kidney injury patient: use of oXiris(R): a single centre case report. Blood Purif 2019; 47(Suppl. 3): 59–64.

25.

Schwindenhammer

Girardot

Chaulier

, et al. oXiris(R) use in septic shock: experience of two French centres. Blood Purif 2019; 47(Suppl. 3): 29–35.

26.

Turani

Barchetta

Falco

, et al. Continuous renal replacement therapy with the adsorbing filter oXiris in septic patients: a case series. Blood Purif 2019; 47(Suppl. 3): 54–58.

27.

Zhang

Yan Tang

Liu

, et al. Hemofilter with adsorptive capacities: case report series. Blood Purif 2019; 47(Suppl. 3): 45–50.

28.

Broman

Bodelsson

Analysis of endotoxin adsorption in two Swedish patients with septic shock. Blood Purif 2019; 47(Suppl. 3): 51–53.

29.

Govil

Gupta

Srinivasan

, et al. 055 cytokine removal in sepsis: does their levels co-relate with outcome. Kidney Int Rep 2017; 2(4, Suppl.): S26.

30.

Govil

Gupta

Srinivasan

, et al. 054 cytokine adsorption in sepsis: correct timing can predict the favorable outcome. Kidney Int Rep 2017; 2(4): S29.

31.

Gambro Industries. oXiris^TM Instructions for use, 2015. https://www.baxter.com/healthcare-professionals/critical-care/oxiris-critical-care

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.20 MB